ESMO 2024 | DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancer
Naoto Ueno, MD, PhD, University of Hawai’i Cancer Center, Honolulu, HI, discusses findings from the DESTINY-Breast04 study (NCT03734029), highlighting higher response rates observed with combining trastuzumab deruxtecan (T-DXd) with immunotherapy (IO). A subset analysis suggests that patients with higher total lymphocyte counts may experience better outcomes with this combination. However, no clear biomarker has yet been identified to guide the use of immune checkpoint inhibitors with T-DXd, and further research is needed to understand which patients will benefit most from this combination. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
